Injection Options
Certain Eye Conditions Will Respond To Medications Injected Directly Into The Eye. These Injections Will Be Given At The Office. They Are Generally Painless And Well Tolerated By Most. There Is A Small Risk For Increased Pressure Inside The Eye And Infections.
Schedule Your Appointment
How does Avastin Work?
Avastin works by blocking the production of a chemical called “vascular endothelial growth factor” (VEGF). Wet age-related macular degeneration is caused by the growth of abnormal blood vessels in the eye, so by blocking this chemical Avastin can slow the growth of blood vessels that can leak and cause vision loss.
How does Treatment with Avastin Work?
Avastin is administered as an outpatient procedure. Your eye will be cleaned and an anesthetic is applied in order to numb the eye, and the drug is administered using a very fine needle. It is common to need repetitive treatment over time when using Avastin, as repeat treatments are typically necessary for continued results.
EYLEA® (aflibercept) Injection
Indicated for the treatment of patients with neovascular (Wet) Age-related Macular Degeneration (AMD).
Indicated for the treatment of patients with Macular Edema following Central Retinal Vein Occlusion (CRVO).
EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
LUCENTIS
The Food and Drug Administration (FDA) approved LUCENTIS for the treatment of patients with neovascular or wet macular degeneration. LUCENTIS was specifically developed for intraocular use. It has been developed to treat the underlying cause of wet macular degeneration by targeting the molecular pathway that controls the formation of new blood vessels. LUCENTIS is designed to bind and inhibit the vascular endothelial growth factor (VEGF), a protein that is believed to play a critical role in the formation of new blood vessels. VEGF has been shown to lead to wet macular degeneration progression and central vision loss.
LUCENTIS is a series of injections given directly into the eye every four weeks. Your physician will tell you how long you will need to receive the injections.
To learn more about Lucentis, please click on the link below:
BEOVU® (brolucizumab-dbll) Injection
BEOVU® (brolucizumab-dbll) injection is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).
Byooviz
Byooviz is a medicine used to treat adults with certain sight problems caused by damage to the retina (the light-sensing layer at the back of the eye), and more specifically its central region, known as the macula. The macula provides the vision needed to see detail for everyday tasks such as driving, reading and recognising faces. Byooviz is used to treat:
- ‘wet’ form of age-related macular degeneration (AMD). The wet form of AMD is caused by choroidal neovascularisation (abnormal growth of blood vessels beneath the retina, which may leak fluid and blood and cause swelling);
- macular oedema (swelling of the macula) caused by diabetes or by occlusion (blockage) of the veins behind the retina;
- proliferative diabetic retinopathy (growth of abnormal tiny blood vessels in the eye, associated with diabetes);
- other sight problems associated with choroidal neovascularisation.
Byooviz is a ‘biosimilar medicine’. This means that Byooviz is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Byooviz is Lucentis.
Byooviz is a solution for injection into the vitreous humour, the jelly-like fluid in the eye. It can only be obtained with a prescription and must be given by a qualified eye doctor who is experienced in giving injections into the eye
CIMERLI™
CIMERLI™ (ranibizumab-eqrn) is interchangeable* to Lucentis® (ranibizumab injection)
CIMERLI™ (ranibizumab-eqrn), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema Following Retinal Vein Occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)
- Myopic Choroidal Neovascularization (mCNV)
What Does OZURDEX® Do?
- The swelling in your retina can be caused by several factors, including inflammation
- OZURDEX® works to help reduce the inflammation in your retina and improve visual acuity
- Once injected, the implant dissolves slowly and releases a corticosteroid called dexamethasone
- Corticosteroids, such as dexamethasone, reduce inflammation
SYFOVRE
SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation.
VABYSMO
VABYSMO is contraindicated in patients with ocular or periocular infection, in patients with active intraocular inflammation, and in patients with known hypersensitivity to faricimab or any of the excipients in VABYSMO. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation.
